Paper Details

  1. Home
  2. Paper Details

Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.

Author: BauerBarbara, ClohertyGavin A, CohenDaniel E, DumasEmily O, HézodeChristophe, KingJennifer, LucicDanijela, MorseGene D, OcqueAndrew, PawlotskyJean-Michel, RejmanRichard M, ShulmanNancy, TalalAndrew H, ZhaJiuhong, ZhangHongtao

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study found that RBV coadministration had minimal impact on the plasma or liver kinetics of HCV RNA decline during the first 2 weeks of treatment, regardless of RBV dosing.
Paper Details　
Original Abstract of the Article :
BACKGROUND: It is unknown whether ribavirin (RBV) coadministration modifies the early rate of decline of hepatitis C virus (HCV) RNA in the liver versus plasma compartments, specifically. METHODS: This partially randomized, open-label, phase 2 study enrolled treatment-naive, noncirrhotic patients w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853515/

データ提供：米国国立医学図書館（NLM）

Hepatitis C Treatment: Navigating the Complexities of Ribavirin

Hepatitis C, a viral infection that attacks the liver, is a serious health concern affecting millions worldwide. It's like a relentless desert wind, slowly eroding the liver's health. This study focuses on a combination therapy for hepatitis C, comprised of ombitasvir/paritaprevir/ritonavir plus dasabuvir, with varying doses of ribavirin, a drug known to inhibit viral replication.

The researchers, like intrepid explorers venturing into the heart of the desert, investigated the impact of ribavirin on the rate of viral decline in both the liver and bloodstream. They found that ribavirin had minimal impact on the initial rate of viral decline in either compartment, regardless of the dosage used. This suggests that while ribavirin plays a role in the overall treatment response, its effect may be more pronounced in the later stages of therapy.

Ribavirin's Role in Hepatitis C Treatment: A Closer Look

The study results suggest that ribavirin, while a valuable component of hepatitis C treatment, may have a less significant impact on early viral decline.

Optimizing Hepatitis C Treatment: A Quest for Efficiency

This study provides valuable insights into the dynamics of hepatitis C treatment, particularly the role of ribavirin. Understanding the complex interactions between different drugs in combination therapy is critical for developing more efficient and effective treatment regimens.

Dr.Camel's Conclusion

This study is a testament to the ongoing quest for more effective and personalized treatment for hepatitis C. By understanding the intricate interplay between different drugs, we can develop tailored treatment plans that minimize side effects and optimize patient outcomes. Just like navigating a desert landscape, we must carefully consider each element of the treatment journey to achieve lasting success.

Date :
  1. Date Completed 2019-04-12
  2. Date Revised 2019-04-12
Further Info :

Pubmed ID

29228392

DOI: Digital Object Identifier

PMC5853515

Related Literature

Article Analysis
・Side Effects of ombitasvir paritaprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.